Mark Zuckerberg and wife Dr. Priscilla Chan recently announced a $3 billion initiative geared towards curing most of the world’s diseases called the Biohub. Through the Chan Zuckerberg Initiative, the couple managed to draw support from other billionaires and ordinary people alike in terms of funding and cooperation. Recently, the Facebook founder released a post detailing how a meeting with top scientists gave him hope that most, if not all of the world’s diseases will be gone by 2115.
The scientists in question are at the top of their fields with regards to dealing with illnesses and they come from multiple origins, including Stanford University and UC Berkeley. Heading the team is Dr. Cori Bargmann, who is a Rockefeller neuroscientist, Futurism reports.
Even with excellent brains behind the operation, the goal of eradicating even just a majority of the known diseases plaguing the world is a monumental undertaking. Much of the challenges has to do with research, which is a costly and time-consuming affair. The Biohub will take on a lot of the weight of the problems that usually prevent scientists from making swift progress, but even then, many would consider the 100-year timeline to be overly ambitious.
Zuckerberg and the team of scientists don’t seem to think so, however, and they point to the advancements that humanity has achieved in the last few decades in extending human lifespan. Global Futurist also notes how the initiative has already addressed one of the hurdles of getting to the point that they are aiming for; coordination.
There’s also the matter of the most recent innovations in medical and bioresearch to consider, which gives the lofty goals of a disease-free world a boost. There’s the new gene-editing tool called CRISPR, which is basically a starter kit for playing God. Then there’s the project called Cell Atlas, which aims to map all of the human body’s cells to address diseases that begin at the cellular level.


Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit
Instagram Outage Disrupts Thousands of U.S. Users
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 



